SG146695A1 - Method of inhibiting remnant lipoprotein production - Google Patents
Method of inhibiting remnant lipoprotein productionInfo
- Publication number
- SG146695A1 SG146695A1 SG200807364-5A SG2008073645A SG146695A1 SG 146695 A1 SG146695 A1 SG 146695A1 SG 2008073645 A SG2008073645 A SG 2008073645A SG 146695 A1 SG146695 A1 SG 146695A1
- Authority
- SG
- Singapore
- Prior art keywords
- lipoprotein production
- remnant lipoprotein
- inhibiting
- remnant
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003373453 | 2003-09-26 | ||
US59081104P | 2004-07-23 | 2004-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG146695A1 true SG146695A1 (en) | 2008-10-30 |
Family
ID=37583964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200807364-5A SG146695A1 (en) | 2003-09-26 | 2004-09-24 | Method of inhibiting remnant lipoprotein production |
Country Status (17)
Country | Link |
---|---|
US (3) | US20070054839A1 (xx) |
EP (3) | EP1670446A2 (xx) |
JP (2) | JP4536061B2 (xx) |
KR (2) | KR20060080214A (xx) |
CN (3) | CN103330703A (xx) |
AU (1) | AU2004275637C1 (xx) |
BR (1) | BRPI0414822A (xx) |
CA (1) | CA2554982A1 (xx) |
CO (1) | CO5690566A2 (xx) |
IL (2) | IL174310A (xx) |
MX (1) | MXPA06003357A (xx) |
NO (1) | NO20061818L (xx) |
NZ (2) | NZ569469A (xx) |
RU (1) | RU2330682C2 (xx) |
SG (1) | SG146695A1 (xx) |
WO (1) | WO2005030185A2 (xx) |
ZA (2) | ZA200603280B (xx) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
WO2006073973A2 (en) | 2004-12-31 | 2006-07-13 | Reddy Us Therapeutics, Inc. | Novel benzylamine derivatives as cetp inhibitors |
US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
JP5498168B2 (ja) | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体 |
CN103827105B (zh) | 2011-08-18 | 2016-08-17 | 雷迪博士实验室有限公司 | 作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物 |
CN103958511A (zh) | 2011-09-27 | 2014-07-30 | 雷迪博士实验室有限公司 | 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物 |
WO2014017569A1 (ja) * | 2012-07-26 | 2014-01-30 | 興和株式会社 | 血中ldlを低下させるための医薬 |
CN111073974B (zh) | 2013-03-27 | 2024-04-09 | 豪夫迈·罗氏有限公司 | 用于预测对于治疗的响应性的遗传标记 |
AU2014247953A1 (en) | 2013-04-05 | 2015-11-12 | Mitobridge, Inc. | PPAR agonists |
MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
EP3770146A1 (en) | 2015-10-07 | 2021-01-27 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
MX2018012538A (es) | 2016-04-13 | 2019-02-25 | Mitobridge Inc | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US165231A (en) * | 1875-07-06 | Improvement in knuckle-couplings for tumbling-shafts | ||
US59810A (en) * | 1866-11-20 | babtlett | ||
US43341A (en) * | 1864-06-28 | Improved vegetable ointment or salve | ||
US40545A (en) * | 1863-11-10 | Joseph h | ||
US120011A (en) * | 1871-10-17 | Improvement in sad-iron handles | ||
US27826A (en) * | 1860-04-10 | Improvement in harvesters | ||
US32644A (en) * | 1861-06-25 | Tub and pail machine | ||
US127574A (en) * | 1872-06-04 | Improvement in machinery for breaking and crushing stones | ||
US18446A (en) * | 1857-10-20 | Improvement in steam-plows | ||
US177708A (en) * | 1876-05-23 | Improvement in hinges | ||
JPH01149743A (ja) | 1987-12-04 | 1989-06-12 | Japan Atom Energy Res Inst | エチレングリコールの製造方法 |
AU661337B2 (en) * | 1991-09-13 | 1995-07-20 | Sankyo Company Limited | 2-(9h-xanthem-9-yl)acetamide and analogues |
JPH05194475A (ja) * | 1991-09-13 | 1993-08-03 | Sankyo Co Ltd | 三環性ヘテロシクリル化合物 |
WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
US5519001A (en) | 1991-12-19 | 1996-05-21 | Southwest Foundation For Biomedical Research | CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
WO1995001326A1 (en) * | 1993-06-30 | 1995-01-12 | The Wellcome Foundation Limited | Anti-atherosclerotic diaryl compounds |
US5446207A (en) | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
EP0717720B1 (en) | 1993-09-01 | 2002-03-13 | Apollo Environmental Systems Corp. | Liquid sulfur degassing |
GB9318277D0 (en) | 1993-09-03 | 1993-10-20 | Ici Plc | Production of difluoromethane |
US5461049A (en) * | 1994-05-27 | 1995-10-24 | Warner-Lambert Company | Amide tetrazole ACAT inhibitors |
EP0733061A1 (en) | 1994-11-12 | 1996-09-25 | LG Chemical Limited | Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents |
JPH0959155A (ja) | 1995-08-23 | 1997-03-04 | Kaken Pharmaceut Co Ltd | コレステリルエステル転送反応阻害剤 |
DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
DE19704243A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | Neue 2-Amino-substituierte Pyridine |
JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
JP3290962B2 (ja) | 1997-02-12 | 2002-06-10 | 日本たばこ産業株式会社 | Cetp活性阻害剤 |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
US6068993A (en) | 1997-07-02 | 2000-05-30 | Biobras Sa | Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin |
US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
DE19741399A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
US5986055A (en) * | 1997-11-13 | 1999-11-16 | Curagen Corporation | CDK2 interactions |
WO1999041237A1 (en) | 1998-02-13 | 1999-08-19 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
AU775607B2 (en) | 1998-09-17 | 2004-08-05 | Pfizer Products Inc. | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as CETP inhibitors |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
PT1115693E (pt) | 1998-09-25 | 2007-08-02 | Monsanto Co | Arial- e heteroaril - heteroalquilaminas terciárias policíclicas substituídas úteis para inibir a actividade da proteína de transferência de éster de colesterilo. |
EP1115694A1 (en) | 1998-09-25 | 2001-07-18 | Monsanto Company | Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
US6356282B2 (en) * | 1998-12-04 | 2002-03-12 | Sun Microsystems, Inc. | Alarm manager system for distributed network management system |
DK1140188T3 (da) | 1998-12-23 | 2003-09-29 | Searle Llc | Kombinationer af ileale galdesyretransporthæmmere og cholesterylestere tranferproteinhæmmere til cardiovaskulære indikationer |
DK1140184T3 (da) | 1998-12-23 | 2003-09-29 | Searle Llc | Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer |
CA2356157C (en) | 1998-12-23 | 2008-04-01 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
HUP0105166A3 (en) | 1999-03-08 | 2003-10-28 | Kitasato Inst | Substances wk-5344a and wk-5344b and process for producing the same |
US20010018446A1 (en) | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
US6544974B2 (en) | 1999-09-23 | 2003-04-08 | G.D. Searle & Co. | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity |
US6451823B1 (en) | 1999-09-23 | 2002-09-17 | G.D. Searle & Co. | Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity |
US6482862B1 (en) | 1999-12-20 | 2002-11-19 | G.D. Searle & Co. | Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
BR0113200A (pt) | 2000-08-15 | 2003-09-16 | Pfizer Prod Inc | Combinação terapêutica |
EP1362846A4 (en) | 2001-01-26 | 2006-10-04 | Takeda Pharmaceutical | AMINOETHANOLDERIVATE |
JP2002293764A (ja) | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
BR0207285A (pt) | 2001-02-15 | 2004-02-10 | Pfizer Producs Inc | Agonistas de ppar |
EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
DK1425270T3 (da) | 2001-04-30 | 2006-07-03 | Pfizer Prod Inc | Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer |
BR0212826A (pt) | 2001-09-26 | 2004-08-24 | Forbes Medi Tech Inc | Método de redução da proteìna de transferência dos ésteres colesterìlicos mediada pela proteìna de transferência do éster do colesterol in vivo entre as lipoproteìnas de alta densidade (hdl) e lipoproteìnas de baixa densidade (ldl) |
DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
JP2003221376A (ja) | 2001-11-21 | 2003-08-05 | Japan Tobacco Inc | Cetp活性阻害剤 |
MXPA04006203A (es) * | 2001-12-21 | 2004-10-15 | Pharmacia Corp | Moduladores aromaticos del receptor x de higado de tioeter. |
ES2277142T3 (es) * | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
DE10250687A1 (de) | 2002-10-31 | 2004-05-13 | Bayer Ag | 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung |
US6727277B1 (en) | 2002-11-12 | 2004-04-27 | Kansas State University Research Foundation | Compounds affecting cholesterol absorption |
KR100857759B1 (ko) * | 2003-03-17 | 2008-09-09 | 니뽄 다바코 산교 가부시키가이샤 | Cetp 억제제의 약제학적 조성물 |
-
2004
- 2004-09-24 CA CA002554982A patent/CA2554982A1/en active Pending
- 2004-09-24 CN CN2013102275998A patent/CN103330703A/zh active Pending
- 2004-09-24 NZ NZ569469A patent/NZ569469A/en not_active IP Right Cessation
- 2004-09-24 AU AU2004275637A patent/AU2004275637C1/en not_active Ceased
- 2004-09-24 BR BRPI0414822-3A patent/BRPI0414822A/pt not_active IP Right Cessation
- 2004-09-24 CN CNA2008101078417A patent/CN101342162A/zh active Pending
- 2004-09-24 KR KR1020067005734A patent/KR20060080214A/ko not_active Application Discontinuation
- 2004-09-24 EP EP04773516A patent/EP1670446A2/en not_active Withdrawn
- 2004-09-24 CN CNA2004800345730A patent/CN1886124A/zh active Pending
- 2004-09-24 MX MXPA06003357A patent/MXPA06003357A/es active IP Right Grant
- 2004-09-24 SG SG200807364-5A patent/SG146695A1/en unknown
- 2004-09-24 KR KR1020077016830A patent/KR20070087197A/ko not_active Application Discontinuation
- 2004-09-24 EP EP11153547A patent/EP2316447A1/en not_active Withdrawn
- 2004-09-24 WO PCT/JP2004/014428 patent/WO2005030185A2/en active Application Filing
- 2004-09-24 JP JP2006515401A patent/JP4536061B2/ja not_active Expired - Fee Related
- 2004-09-24 EP EP11153508A patent/EP2319509A1/en not_active Withdrawn
- 2004-09-24 NZ NZ546732A patent/NZ546732A/en not_active IP Right Cessation
- 2004-09-24 RU RU2006114044/15A patent/RU2330682C2/ru not_active IP Right Cessation
-
2006
- 2006-03-14 IL IL174310A patent/IL174310A/en not_active IP Right Cessation
- 2006-03-24 US US11/389,542 patent/US20070054839A1/en not_active Abandoned
- 2006-04-21 CO CO06037892A patent/CO5690566A2/es unknown
- 2006-04-25 ZA ZA200603280A patent/ZA200603280B/xx unknown
- 2006-04-25 ZA ZA200806375A patent/ZA200806375B/xx unknown
- 2006-04-25 NO NO20061818A patent/NO20061818L/no not_active Application Discontinuation
-
2008
- 2008-08-31 IL IL193771A patent/IL193771A/en not_active IP Right Cessation
-
2010
- 2010-01-12 JP JP2010004396A patent/JP5214638B2/ja not_active Expired - Fee Related
- 2010-09-24 US US12/890,379 patent/US20110189210A1/en not_active Abandoned
-
2014
- 2014-01-15 US US14/155,744 patent/US20140364493A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG146695A1 (en) | Method of inhibiting remnant lipoprotein production | |
TN2009000012A1 (en) | Amino-piperidine derivatives as cetp inhibitors | |
UA92083C2 (ru) | Азабициклические алкановые производные, замещенные конденсированным бициклогетероциклом | |
MX2010006063A (es) | Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis. | |
TW200800947A (en) | Trisubstituted amine compound | |
EA200500268A1 (ru) | Производные диоксан-2-алкилкарбаматов, способ их получения и применение в терапии | |
MX2012002752A (es) | Compuestos de heteroarilo como inhibidores de cinasa. | |
EA201100189A1 (ru) | Гетероарильные производные в качестве ингибиторов dgat1 | |
NO20051146L (no) | Fremgangsmate for fremstilling av mellomprodukter nyttige for fremstilling av tubulininhibitorer | |
DE60016039D1 (de) | Verfahren und verbindungen für die hemmung von mrp1 | |
MA27257A1 (fr) | Composes utiles pour le traitement du charbon et l'inhibition du gene letal | |
FR2942625B1 (fr) | Derives indoliques pour le traitement de maladies neurodegeneratives | |
EA200600878A1 (ru) | Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar ) | |
DE60113407D1 (de) | Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten | |
MX2021008386A (es) | Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b. | |
TW200730177A (en) | 4 anilino-3-quinolinecarbonitriles for the treatment of cancer | |
RS20050563A (xx) | Derivati acilaminotiazola, njihovo dobijanje i njihova upotreba kao inhibitora proizvodnje beta- amiloid peptida | |
MXPA05003909A (es) | Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer. | |
DE602004014822D1 (de) | Neues verfahren zur herstellung von nitrooxyderivaten von paracetamol | |
ATE168982T1 (de) | Neues verfahren zur herstellung von beta- alkoxyacrylsäure | |
EA200501083A1 (ru) | Соединения, активные в ингибировании пролилолигопептидазы | |
DE602004030112D1 (de) | Verfahren zur herstellung von ace hemmern | |
EA200601248A1 (ru) | Новые многократно замещённые соединения 1,1-пиридилоксициклопропанамина, способ их получения и фармацевтические композиции, которые их содержат | |
ATE279182T1 (de) | Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c | |
DE60106293D1 (de) | Verfahren zur inhibierung von katarakten |